Phase 2 Study of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using TLI & ATG
| Status: | Completed |
|---|---|
| Conditions: | Blood Cancer, Hematology |
| Therapuetic Areas: | Hematology, Oncology |
| Healthy: | No |
| Age Range: | 18 - 75 |
| Updated: | 10/22/2017 |
| Start Date: | May 2009 |
| End Date: | December 2014 |
A Phase 2 Study of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using Total Lymphoid Irradiation (TLI) and Antithymocyte Globulin (ATG) in Multiple Myeloma Patients
To evaluate the toxicity and tolerability of this tandem autologous/allogeneic transplant
approach for patients with advanced stage multiple myeloma.
approach for patients with advanced stage multiple myeloma.
Development of cell-based immunotherapy from allogeneic hematopoietic cell transplantation
(HCT) is dependent upon stable T-cell engraftment and the success of this therapeutic
approach is likely to be greatest when directed against a minimal rather than gross tumor
burden. To this end, tandem transplants with high dose therapy and autologous hematopoietic
cell transplantation (AHCT) for tumor cytoreduction followed by non-myeloablative
allotransplant have been conducted. In myeloma, this tandem approach results in greater
efficacy compared to conventional AHCT.
(HCT) is dependent upon stable T-cell engraftment and the success of this therapeutic
approach is likely to be greatest when directed against a minimal rather than gross tumor
burden. To this end, tandem transplants with high dose therapy and autologous hematopoietic
cell transplantation (AHCT) for tumor cytoreduction followed by non-myeloablative
allotransplant have been conducted. In myeloma, this tandem approach results in greater
efficacy compared to conventional AHCT.
PARTICIPANT INCLUSION CRITERIA
- Stage II-III multiple myeloma or have progression after initial treatment of Stage I
disease (Durie Salmon Staging). Patients with plasma cell leukemia are also included.
- Multiple myeloma / plasma cell leukemia diagnosis confirmed by pathology reviewed at
Stanford University Medical Center.
- 18 to ≤ 75 years of age
- Karnofsky Performance Status > 70%.
- Corrected Carbon monoxide diffusing capacity (Dlco) > 60%
- Left ventricle ejection fraction (LVEF) > 50%.
- Alanine aminotransferase (ALT) ≤ 2 x normal
- Aspartate aminotransferase (AST) ≤ 2 x normal
- Total bilirubin ≤ 2 mg/dL, unless hemolysis or Gilbert's disease.
- Estimated creatinine clearance > 50 mL/min.
- Identified related or unrelated Human leukocyte antigen (HLA)-identical donor or donor
with one antigen/allele mismatch in (HLA-A, B, C or DRB1).
- Signed informed consent.
DONOR INCLUSION CRITERIA
- At least 17 years of age
- HIV-seronegative
- Must be capable of giving signed, informed consent
- No contraindication to the administration of filgrastim
- Willing to have a central venous catheter placed for apheresis if peripheral veins are
inadequate
PARTICIPANT EXCLUSION CRITERIA
- Prior allogeneic hematopoietic cell transplantation
- Uncontrolled active infection
- Uncontrolled congestive heart failure or angina
- HIV-positive
- Pregnant or nursing
DONOR EXCLUSION CRITERIA
- Serious medical or psychological illness
- Pregnant or lactating
- Prior malignancies within the last 5 years except for non-melanoma skin cancers
We found this trial at
1
site
Stanford University School of Medicine Vast in both its physical scale and its impact on...
Click here to add this to my saved trials
